[{"id":"782a5910-2d52-48ba-920f-6059206b0762","acronym":"","url":"https://clinicaltrials.gov/study/NCT03900377","created_at":"2021-01-18T19:12:21.160Z","updated_at":"2024-07-02T16:35:28.220Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma","source_id_and_acronym":"NCT03900377","lead_sponsor":"SymBio Pharmaceuticals","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • Bendeka (bendamustine rapid infusion)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 02/26/2021","study_completion_date":" 02/26/2021","last_update_posted":"2023-11-24"}]